Literature DB >> 21763682

Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.

Qi Li1, Wei Wang, Tadaaki Yamada, Kunio Matsumoto, Katsuya Sakai, Yoshimi Bando, Hisanori Uehara, Yasuhiko Nishioka, Saburo Sone, Shotaro Iwakiri, Kazumi Itoi, Teruhiro Utsugi, Kazuo Yasumoto, Seiji Yano.   

Abstract

The tumor microenvironment is crucial to the progression of various malignancies. Malignant pleural mesothelioma (MPM), which originates from the pleura, grows aggressively in the thoracic cavity. Here we describe an orthotopic implantation SCID mouse model of MPM and demonstrate that α-SMA-positive fibroblast-like cells accumulate in the tumors produced by the human MPM cell lines MSTO-211H and Y-Meso-14. We assessed the interaction between MPM cells and their microenvironments, focusing on tumor-associated fibroblasts. MSTO-211H and Y-Meso-14 cells produced fibroblast growth factor-2 (FGF-2) and/or platelet-derived growth factor-AA (PDGF-AA); they also enhanced growth, migration, and production of hepatocyte growth factor (HGF) by human lung fibroblast MRC-5 cells. MRC-5 cells stimulated HGF-mediated growth and migration of MSTO-211H and Y-Meso-14 cells in an in vitro coculture system. In the orthotopic model, tumor formation by MSTO-211H and Y-Meso-14 cells was significantly inhibited by TSU-68, an inhibitor of FGF, VEGF, and PDGF receptors; imatinib, an inhibitor of PDGF receptors; and NK4, an antagonist of HGF. Histological analyses of clinical specimens from 51 MPM patients revealed considerable tumor-associated fibroblasts infiltration and expression of HGF, together with FGF-2 or PDGF-AA, in tumors. These findings indicate that MPM instigates tumor-associated fibroblasts, promoting tumor progression via a malignant cytokine network. Regulation of this cytokine network may be therapeutically useful for controlling MPM.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763682      PMCID: PMC3157262          DOI: 10.1016/j.ajpath.2011.05.060

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  A rapid in vitro assay for quantitating the invasive potential of tumor cells.

Authors:  A Albini; Y Iwamoto; H K Kleinman; G R Martin; S A Aaronson; J M Kozlowski; R N McEwan
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

2.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation.

Authors:  Shinsuke Kato; Hiroshi Funakoshi; Toshikazu Nakamura; Masako Kato; Imaharu Nakano; Asao Hirano; Eisaku Ohama
Journal:  Acta Neuropathol       Date:  2003-04-18       Impact factor: 17.088

4.  Molecular cloning and expression of human hepatocyte growth factor.

Authors:  T Nakamura; T Nishizawa; M Hagiya; T Seki; M Shimonishi; A Sugimura; K Tashiro; S Shimizu
Journal:  Nature       Date:  1989-11-23       Impact factor: 49.962

Review 5.  The pathogenesis of mesothelioma.

Authors:  Michele Carbone; Robert A Kratzke; Joseph R Testa
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

6.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

7.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

Review 8.  Current approach to malignant mesothelioma of the pleura.

Authors:  J Aisner
Journal:  Chest       Date:  1995-06       Impact factor: 9.410

9.  Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.

Authors:  Yoshinori Suzuki; Katsuya Sakai; Junko Ueki; Qing Xu; Takahiro Nakamura; Hideaki Shimada; Toshikazu Nakamura; Kunio Matsumoto
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

10.  Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients.

Authors:  G Eagles; A Warn; R Y Ball; H Baillie-Johnson; N Arakaki; Y Daikuhara; R M Warn
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more
  23 in total

Review 1.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.

Authors:  Tadaaki Yamada; Joseph M Amann; Koji Fukuda; Shinji Takeuchi; Naoya Fujita; Hisanori Uehara; Shotaro Iwakiri; Kazumi Itoi; Konstantin Shilo; Seiji Yano; David P Carbone
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

3.  Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Authors:  Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly
Journal:  J Thorac Oncol       Date:  2017-06-06       Impact factor: 15.609

4.  A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

Authors:  Emilie M J van Brummelen; Evgeny Levchenko; Manuel Dómine; Dean A Fennell; Hedy L Kindler; Santiago Viteri; Shirish Gadgeel; Pilar Garrido López; Vladimir Kostorov; Daniel Morgensztern; Sergey Orlov; Marjorie G Zauderer; Johan F Vansteenkiste; Katherine Baker-Neblett; James Vasquez; Xiaowei Wang; David I Bellovin; Jan H M Schellens; Li Yan; Ionel Mitrica; M Phillip DeYoung; José Trigo
Journal:  Invest New Drugs       Date:  2019-05-07       Impact factor: 3.850

Review 5.  Three-Dimensional Cell Culture Models of Hepatocellular Carcinoma - a Review.

Authors:  Irmak Ayvaz; Dilara Sunay; Ece Sariyar; Esra Erdal; Zeynep Firtina Karagonlar
Journal:  J Gastrointest Cancer       Date:  2021-12-20

Review 6.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Authors:  Lindsay A Marek; Trista K Hinz; Anne von Mässenhausen; Kyle A Olszewski; Emily K Kleczko; Diana Boehm; Mary C Weiser-Evans; Raphael A Nemenoff; Hans Hoffmann; Arne Warth; Joseph M Gozgit; Sven Perner; Lynn E Heasley
Journal:  Mol Cancer Res       Date:  2014-06-25       Impact factor: 5.852

8.  Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor β.

Authors:  Romy B Christmann; Allison Mathes; Alsya J Affandi; Cristina Padilla; Banafsheh Nazari; Andreea M Bujor; Giuseppina Stifano; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2013-05

Review 9.  The role of the cell-cell interactions in cancer progression.

Authors:  Katarzyna Kamińska; Cezary Szczylik; Zofia F Bielecka; Ewa Bartnik; Camillo Porta; Fei Lian; Anna M Czarnecka
Journal:  J Cell Mol Med       Date:  2015-01-19       Impact factor: 5.310

10.  Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion.

Authors:  Chang-Chang Jia; Tian-Tian Wang; Wei Liu; Bin-Sheng Fu; XueFeng Hua; Guo-Ying Wang; Tuan-Jie Li; Xing Li; Xiang-Yuan Wu; Yan Tai; Jie Zhou; Gui-Hua Chen; Qi Zhang
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.